COVID-19 roundup: Qiagen ships diagnostic to China; plus Gilead starts own remdesivir trials and Ascletis clinical update

Qiagen said Wednesday it is seeking emergency FDA clearance for its coronavirus diagnostic. Separately, Gilead started a pair of Phase III trials of remdesivir to treat COVID-19, bringing the total number of trials testing the antiviral to five, and Ascletis announced clinical results for protease inhibitor Ganovo.

Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said it will apply for emergency marketing authorization in the U.S., South Korea and China for a new version of its QIAstat-Dx respiratory panel that can test for the presence of SARS-CoV-2. The company said it has already shipped the panel to four hospitals in China for evaluation and is in the process of shipping to other regions including Southeast Asia and the Middle East...